Article 1
Open ↗Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.
Source
Commission Regulation (EU) 2015/1221 of 24 July 2015 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress (Text with EEA relevance)
Commission Regulation (EU) 2015/1221 of 24 July 2015 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress (Text with EEA relevance)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Article 2
Open ↗By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).
Article 3
Open ↗1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . 2. Article 1 shall apply in respect of substances and mixtures from 1 January 2017.
Supplementary provisions
ANNEXSupplementary provisions
Open ↗ANNEX Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) Table 3.1 is amended as follows: (a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries: Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) 007-004-00-1 nitric acid … % 231-714-2 7697-37-2 Ox. Liq. 2 Skin Corr. 1A H272 H314 GHS03 GHS05 Dgr H272 H314 EUH071 Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 % B 015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 H260 H300 H311 H330 H318 H400 GHS02 GHS06 GHS05 GHS09 Dgr H260 H300 H311 H330 H318 H400 EUH029 EUH032 M = 100 031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. 1B Carc. 1B STOT RE 1 H360F H350 H372 (respiratory and haematopoietic systems) GHS08 Dgr H360F H350 H372 (respiratory and haematopoietic systems) 050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H360FD H301 H312 H372** H315 H319 H400 H410 GHS08 GHS06 GHS09 Dgr H360FD H301 H312 H372** H315 H319 H410 * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 A 1 603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 H225 H351 H302 H312 H332 H335 H315 H319 GHS02 GHS08 GHS07 Dgr H225 H351 H302 H312 H332 H335 H315 H319 603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H361d*** H302 H400 H410 GHS08 GHS07 GHS09 Wng H361d*** H302 H410 M = 1 M = 10 606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone — 141112-29-0 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d*** H400 H410 GHS08 GHS09 Wng H361d*** H410 M = 10 M = 100 607-197-00-8 nonanoic acid 203-931-2 112-05-0 Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 H315 H319 H412 GHS07 Wng H315 H319 H412 613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1 H -imidazole 252-615-0 35554-44-0 Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 H351 H301 H332 H318 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H301 H332 H318 H410 M = 10 613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H361d H373 (liver) H314 H317 H400 H410 GHS08 GHS05 GHS07 GHS09 Dgr H361d H373 (liver) H314 H317 H410 EUH071 M = 1 M = 1 613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H317 H410 M = 1 M = 1 613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H331 H301 H400 H410 GHS06 GHS09 Dgr H331 H301 H410 M = 1 000 M = 1 000 (b) the following entries are inserted in accordance with the order of the entries set out in Table 3.1: Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) 019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Eye Irrit. 2 H319 GSH07 Wng H319 604-092-00-9 phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1] 121158-58-5 [1] 74499-35-7 [2] Skin Corr. 1C Aquatic Acute 1 Aquatic Chronic 1 H314 H400 H410 GHS05 GHS09 Dgr H314 H410 M = 10 M = 10 606-148-00-8 carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] Skin Sens. 1 H317 GHS07 Wng H317 606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione — 335104-84-2 Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H373 (eyes, kidneys, liver) H317 H400 H410 GHS08 GHS07 GHS09 Wng H361d H373 (eyes, kidneys, liver) H317 H410 M = 100 M = 10 607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H373 (kidneys) H317 H400 H410 GHS08 GHS07 GHS09 Wng H373 (kidneys) H317 H410 M = 1 M = 1 607-708-00-4 octanoic acid 204-677-5 124-07-2 Skin Corr. 1C Aquatic Chronic 3 H314 H412 GHS05 Dgr H314 H412 607-709-00-X decanoic acid 206-376-4 334-48-5 Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 H315 H319 H412 GHS07 Wng H315 H319 H412 607-710-00-5 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. 1B H360FD GHS08 Dgr H360FD 607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H361fd H335 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H361fd H335 H319 H317 H410 M = 1 M = 1 607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 H361d H373 (liver) H314 H317 H410 GHS08 GHS05 GHS07 GHS09 Dgr H361d H373 (liver) H314 H317 H410 EUH071 M = 1 607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H301 H330 H317 H400 H410 GHS06 GHS09 Dgr H301 H330 H317 H410 M = 100 M = 1 000 607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 100 M = 10 607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H373 H317 H400 H410 GHS08 GHS07 GHS09 Wng H373 H317 H410 M = 1 M = 1 613-319-00-0 imidazole 206-019-2 288-32-4 Repr. 1B Acute Tox. 4 Skin Corr. 1C H360D H302 H314 GHS08 GHS07 GHS05 Dgr H360D H302 H314 613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 10 M = 10 616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)- N -{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H373 (eyes, kidneys) H400 H410 GHS08 GHS09 Wng H351 H373 (eyes, kidneys) H410 M = 1 000 M = 100 616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 H410 M = 10 M = 10 616-216-00-9 flonicamid (ISO); N -(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Acute Tox. 4 H302 GHS07 Wng H302 616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 M = 1 M = 1 (2) Table 3.2 is amended as follows: (a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries: Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes 007-004-00-1 nitric acid … % 231-714-2 7697-37-2 O; R8 C; R35 O; C R: 8-35 S: (1/2-)26-28- 36/37/39-45-63 O; R8: C ≥ 65 % C; R35: C ≥ 20 % C; R34: 5 % ≤ C < 20 % B 015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 F; R15/29 T+; R26/28 Xn; R21 R32 Xi; R38-41 N; R50 F; T+; N R: 15/29-21-26/28-32-38-41-50 S:(1/2-)26-28-30-36/37/39-43-45-60-61 N; R50: C ≥ 0,25 % 031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. Cat. 2; R60 Carc. Cat. 2; R45 T; R48/23 T R: 45-48/23-60 S: 45-53 E 050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. Cat. 2; R60-61 T; R25-48/23/25 Xn; R21 Xi; R36/38 N; R50-53 T; N R: 21-25-36/38-48/23/25-50/53-60-61 S: 45-53-60-61 T; R25: C ≥ 2,5 % Xn; R22: 0,25 % ≤ C < 2,5 % Xn: R21: C ≥ 1 % T; R48/23/25: C ≥ 1 % Xn; R48/20/22: 0,25 % ≤ C < 1 % Xi; R36/38: C ≥ 1 % N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % A 1 603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 F; R11 Carc. Cat. 3; R40 Xn; R20/21/22 Xi; R36/37/38 F; Xn R: 11-20/21/22-36/37/38-40- S: (2-)9-16-29-36/37-46 603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. Cat. 3; R63 Xn; R22 N; R50-53 Xn; N R: 22-50/53-63 S: (2-)22-36/37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % 606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl- p -tolyl ketone — 141112-29-0 Repr. Cat. 3; R63 N; R50-53 Xn; N R: 50/53-63 S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 607-197-00-8 nonanoic acid 203-931-2 112-05-0 Xi; R36/38 N; R51-53 Xi; N R: 36/38-51/53 S: (2-)46-61 613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1 H -imidazole 252-615-0 35554-44-0 Carc. Cat. 3; R40 Xn; R20/22 Xi; R41 N; R51-53 Xn; N R: 20/22-40-41-51/53 S: (2-)26-36/37/39-46-61 613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. Cat. 3; R63 C; R34 R43 N; R50-53 C; N R: 34-43-50/53-63 S: (1/2-)26-28-36/37/39-45-60-61 C; R34: C ≥ 10 % Xi; R36/37/38: 5 % ≤ C < 10 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. Cat. 3; R40 Xn; R22 R43 N; R50-53 Xn; N R: 22-40-43-50/53 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 T; R23/25 N; R50-53 T; N R: 23/25-50/53 S: (1/2-)36/37-45-60-61 N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52-53: 0,00025 % ≤ C < 0,0025 % (b) the following entries are inserted in accordance with the order of the entries set out in Table 3.2: Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes 019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Xi; R36 Xi R: 36 S: (2-)25-46 604-092-00-9 phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1]-[2] 121158-58-5 [1] 74499-35-7 [2] C; R34 N; R50-53 C; N R: 34-50/53 S: (1/2-)26-36/37/39-45-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 606-148-00-8 carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] R43 Xi R: 43 S: (2-)24-37 606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione 335104-84-2 Repr. Cat. 3; R63 Xn; R48/22 R43 N; R50-53 Xn; N R: 43-48/22-50/53-63 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 Xn; R48/22 R43 N; R50-53 Xn; N R: 43-48/22-50/53 S: (2-)24-37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 607-708-00-4 octanoic acid 204-677-5 124-07-2 C; R34 N; R51-53 C; N R: 34-51/53 S: (1/2-)26-36/37/39-45-61 607-709-00-X decanoic acid 206-376-4 334-48-5 Xi; R36/38 N; R51-53 Xi; N R: 36/38-51/53 S: (2-)25-46-61 607-710-00-5 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. Cat. 2; R60-61 T R: 60-61 S: 53-45 607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. Cat. 3; R62-63 Xi; R36/37 R43 N; R50-53 Xn; N R: 36/37-43-50/53-62-63 S: (2-)36/37-60-61 Xi; R43: C ≥ 0,1 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. Cat. 3; R63 C; R34 R43 N; R51-53 C; N R: 34-43-51/53-63 S: (1/2-)26-28-36/37/39-45-61 C; R34: C ≥ 10 % Xi: R36/37/38: 5 % ≤ C < 10 % 607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 T+; R26 Xn; R22 R43 N; R50-53 T+; N R: 22-26-43-50/53 S: (1/2-)28-36/37-45-60-61-63 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)36/37-60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 R43 N; R50-53 Xi; N R: 43-50/53 S: (2-)24-37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-319-00-0 imidazole 206-019-2 288-32-4 Repr. Cat 2; R61 Xn; R22 C; R34 T; C R: 22-34-61 S: 53-45 613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)- N -{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 N; R50-53 N R: 50/53 S: 60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % 616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. Cat. 3; R40 Xn; R48/22 N; R50-53 Xn; N R: 40-48/22-50/53 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52/53: 0,00025 % ≤ C < 0,0025 % 616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Xn; R22 R43 N; R50-53 Xn; N R: 22-43-50/53 S: (2-)24-37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 616-216-00-9 flonicamid (ISO); N -(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Xn; R22 Xn R: 22 S: (2-)46 616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Xn; R22 N; R50-53 Xn; N R: 22-50/53 S: (2-)60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
Other acts of the same type
Commission Implementing Regulation (EU) 2020/1340 of 22 September 2020 entering a name in the register of protected designations of origin and protected geographical indications [‘Brački varenik’ (PGI)]Council Implementing Regulation (EU) 2020/1309 of 21 September 2020 implementing Article 21(2) of Regulation (EU) 2016/44 concerning restrictive measures in view of the situation in LibyaCouncil Regulation (EU) 2020/1311 of 21 September 2020 amending Regulation (EU) No 224/2014 concerning restrictive measures in view of the situation in the Central African RepublicCouncil Regulation (EU) 2020/1323 of 21 September 2020 amending Regulation (EU) 2020/123 as regards certain fishing opportunities for 2020 in Union and non-Union watersCommission Implementing Regulation (EU) 2020/1337 of 21 September 2020 approving non-minor amendments to the specification for a name entered in the register of protected designations of origin and protected geographical indications (‘Casatella Trevigiana’ (PDO))Commission Implementing Regulation (EU) 2020/1338 of 21 September 2020 approving non-minor amendments to the specification for a name entered in the register of protected designations of origin and protected geographical indications (‘Pecorino Siciliano’ (PDO))Commission Implementing Regulation (EU) 2020/1577 of 21 September 2020 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs TariffCommission Implementing Regulation (EU) 2020/1327 of 18 September 2020 entering a name in the register of protected designations of origin and protected geographical indications ‘Akasztói szikiponty’ (PDO)Commission Implementing Regulation (EU) 2020/1328 of 18 September 2020 approving non-minor amendments to the specification for a name entered in the register of protected designations of origin and protected geographical indications (‘Fraise du Périgord’ (PGI))Commission Delegated Regulation (EU) 2020/1732 of 18 September 2020 supplementing Regulation (EU) 2017/2402 of the European Parliament and of the Council with regard to fees charged by the European Securities and Markets Authority to securitisation repositories (Text with EEA relevance)Commission Implementing Regulation (EU) 2020/1297 of 17 September 2020 amending for the 316th time Council Regulation (EC) No 881/2002 imposing certain specific restrictive measures directed against certain persons and entities associated with the ISIL (Da'esh) and Al-Qaida organisationsCommission Implementing Regulation (EU) 2020/1321 of 17 September 2020 entering a name in the register of protected designations of origin and protected geographical indications (‘Aydın Kestanesi’ (PDO))
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
What to look at next
Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislationEU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and yearEuropean Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview